Clinical Trial Update: Effectiveness of KOS-862 in the Treatment of Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating KOS-862 for lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• KOS-862 (Epothilone D)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED